Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648464 | 0.89 | NR4A2 (0.46) | NR4A2MAOAMAOBL3MBTL1PKM | |
| SCHEMBL21039095 | 0.89 | NR4A2 (0.46) | NR4A2MAOAMAOBL3MBTL1PKM | |
| SCHEMBL19659875 | 0.84 | PARP10 (0.51) | NR4A2MAOAMAOBL3MBTL1PKM | |
| SCHEMBL19659221 | 0.81 | L3MBTL1 (0.43) | NR4A2MAOAMAOBL3MBTL1PKM | |
| SCHEMBL27917764 | 0.81 | KMT2A (0.56) | NR4A2MAOAMAOBL3MBTL1MAPT | |
| SCHEMBL5725796 | 0.81 | L3MBTL1 (0.58) | NR4A2MAOBL3MBTL1PKMPARP10 | |
| SCHEMBL5725907 | 0.80 | PSMB1 (0.61) | MAPTSMN1; SMN2 | |
| SCHEMBL5725910 | 0.79 | CHEK2 (0.48) | NR4A2MAOAMAOBTP53 | |
| SCHEMBL21002113 | 0.78 | FFAR4 (0.48) | L3MBTL1PKMGAARAB9ANPC1 | |
| SCHEMBL2085224 | 0.78 | L3MBTL1 (0.62) | L3MBTL1PKMMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
| EP-1235776-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Hormos Medical Corporation (FI) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001036360-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORPORATION (FI) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | NR4A2 36/4885MAOA 3948/4885MAOB 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.